Premium
Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future
Author(s) -
Pokorny Adrian M. J.,
Chin Venessa T.,
Nagrial Adnan M.,
Yip Desmond,
Chantrill Lorraine A.
Publication year - 2018
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.13810
Subject(s) - medicine , folfirinox , oxaliplatin , folinic acid , irinotecan , gemcitabine , oncology , pancreatic cancer , adenocarcinoma , pancreatic ductal adenocarcinoma , disease , chemotherapy , cancer , fluorouracil , colorectal cancer
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5‐year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab‐paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental. This review discusses the evidence behind the currently used regimens, while introducing the potential future of pancreatic cancer care.